336 related articles for article (PubMed ID: 23365250)
1. Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease.
Douaud G; Menke RA; Gass A; Monsch AU; Rao A; Whitcher B; Zamboni G; Matthews PM; Sollberger M; Smith S
J Neurosci; 2013 Jan; 33(5):2147-55. PubMed ID: 23365250
[TBL] [Abstract][Full Text] [Related]
2. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
[TBL] [Abstract][Full Text] [Related]
3. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
Marizzoni M; Ferrari C; Macis A; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Pizzini F; Rossini PM; Salvatore M; Schönknecht P; Soricelli A; Del Percio C; Hensch T; Hegerl U; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
J Alzheimers Dis; 2019; 69(1):49-58. PubMed ID: 30958351
[TBL] [Abstract][Full Text] [Related]
4. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
[TBL] [Abstract][Full Text] [Related]
5. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
6. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia.
Kim HJ; Lee JH; Cheong EN; Chung SE; Jo S; Shim WH; Hong YJ
Curr Alzheimer Res; 2020; 17(10):893-903. PubMed ID: 33256581
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
9. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
[TBL] [Abstract][Full Text] [Related]
11. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
van Maurik IS; Vos SJ; Bos I; Bouwman FH; Teunissen CE; Scheltens P; Barkhof F; Frolich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Frisoni GB; Spiru L; Freund-Levi Y; Wallin AK; Hampel H; Soininen H; Tsolaki M; Verhey F; Kłoszewska I; Mecocci P; Vellas B; Lovestone S; Galluzzi S; Herukka SK; Santana I; Baldeiras I; de Mendonça A; Silva D; Chetelat G; Egret S; Palmqvist S; Hansson O; Visser PJ; Berkhof J; van der Flier WM;
Lancet Neurol; 2019 Nov; 18(11):1034-1044. PubMed ID: 31526625
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer's disease.
Reas ET; Hagler DJ; White NS; Kuperman JM; Bartsch H; Cross K; Loi RQ; Balachandra AR; Meloy MJ; Wierenga CE; Galasko D; Brewer JB; Dale AM; McEvoy LK
Alzheimers Res Ther; 2017 Aug; 9(1):55. PubMed ID: 28764771
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
16. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.
Selnes P; Aarsland D; Bjørnerud A; Gjerstad L; Wallin A; Hessen E; Reinvang I; Grambaite R; Auning E; Kjærvik VK; Due-Tønnessen P; Stenset V; Fladby T
J Alzheimers Dis; 2013; 33(3):723-36. PubMed ID: 23186987
[TBL] [Abstract][Full Text] [Related]
17. Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration.
Santana I; Baldeiras I; Santiago B; Duro D; Freitas S; Pereira MT; Almeida MR; Oliveira CR
J Alzheimers Dis; 2018; 64(s1):S647-S657. PubMed ID: 29562515
[TBL] [Abstract][Full Text] [Related]
18. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
[TBL] [Abstract][Full Text] [Related]
19. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
[TBL] [Abstract][Full Text] [Related]
20. Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.
Bertens D; Knol DL; Scheltens P; Visser PJ;
Alzheimers Dement; 2015 May; 11(5):511-22. PubMed ID: 25150730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
